Abstract
The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Current Pharmaceutical Design
Title:Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Volume: 18 Issue: 12
Author(s): Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl
Affiliation:
Keywords: NMDA receptor, schizophrenia, glutamate, genetics, Dopamine Hypothesis, neurodevelopmental abnormalities, ion channel, homeostasis, psychosis, psychiatric symptoms
Abstract: The Dopamine Hypothesis has been the leading theory used to explain the mechanism of the clinical manifestation of schizophrenia symptoms for decades. It is unclear if excess dopaminergic activity is the primary pathophysiology causing psychosis or if this dopamine excess is triggered by upstream, downstream or neurodevelopmental abnormalities. A corollary hypothesis suggests that the glutamatergic system may be involved in the pathogenesis of schizophrenia, and that dysfunction of the glutamate system may actually lead to dopamine excess. The NMDA Receptor Hypofunction Hypothesis suggests that malfunctioning NMDA receptors may be the cause for the theoretically hypofunctioning glutamate system. This paper seeks to describe and discuss the potential underlying genetic vulnerabilities of the NMDA receptor and how aberrant genes coding for this receptor may lead to schizophrenia symptoms.
Export Options
About this article
Cite this article as:
Thomas L. Schwartz, Shilpa Sachdeva, Stephen M. Stahl , Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958594
DOI https://dx.doi.org/10.2174/138161212799958594 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Current Gene Therapy Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study
Current Alzheimer Research Sex, Stress and their Influence on Respiratory Regulation
Current Pharmaceutical Design Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Non-Pharmacological Treatments for ADHD in Youth
Adolescent Psychiatry Wnt Signaling in Angiogenesis
Current Drug Targets Baroreflex Function: Determinants in Healthy Subjects and Disturbances in Diabetes, Obesity and Metabolic Syndrome
Current Diabetes Reviews Local Drug Delivery to Inner Ear for Treatment of Hearing Loss
Current Drug Therapy Treatment of Hypertension Induced Target Organ Damage in Children and Adolescents
Current Pharmaceutical Design Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology Opportunities for Photoacoustic-Guided Drug Delivery
Current Drug Targets Neuroimaging of Consciousness and Sleep Spindles
Recent Patents on Medical Imaging Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Neonatal Environment and Neuroendocrine Programming of the Peripheral Respiratory Control System
Current Pediatric Reviews Guiding Lineage Specific Differentiation of SHED for Target Tissue/Organ Regeneration
Current Stem Cell Research & Therapy The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Bedside Balance Testing in Elderly People
Current Aging Science Tryptophan Catabolites and Migraine
Current Pharmaceutical Design